NEWS YOU CAN USE 2016 02 UPD

download report

Transcript NEWS YOU CAN USE 2016 02 UPD

News You Can Use…
Persida Tahiri, PharmD Candidate 2016
Pete Koval, PharmD
Cone Health Family Medicine
February 2016
P & T Committee
• Veltassa (patiromer) added to the
formulary
• New oral potassium binder FDA
approved for treatment of chronic
hyperkalemia in adults
• Not for acute treatment
• Use at Cone Health: only as continuation
of prior to admission therapy
01/20/16 Cone Health P & T
P & T Committee
• Praxbind (idarucizumab) gained FDA
approval as first available reversal
agent for oral anticoagulant Pradaxa
(dabigatran)
• Use at Cone Health: Only for patients
who have taken dabigatran and have
uncontrollable or life-threatening
bleeding or require immediate invasive
procedure
01/20/16 Cone Health P & T
New Indication
• Consentyx (secukinumab) gained FDA
approval for ankylosing spondylitis
(psoriatic arthritis)
• Already approved for treatment of
moderate to severe plaque psoriasis
in adult patients
1.20.2016 Medscape.com, N Engl J Med. 2015;373:2534-2548
New Guidelines
• New AHA/ASA statement on expanding
use of tPA in stroke
• New Alteplase patient information has
entirely removed some exclusions and
contraindications including:
• Prior stroke
• Seizure at onset of stroke
• History of ICH (left warning for recent ICH)
• Low blood glucose (previously < 50 mg/dL)
• Mild stroke
• Neuroimaging findings
1/15/2016 Stroke Feb 2016
Pen Device Approval
• FDA approves first U-500 insulin pen
device
• Humulin R U-500 KwikPen by Eli Lilly
• It is the same size as the other Lilly
KwikPens and dials in five-unit
increments
01/27/2015 medscape.com
New Research
• Kalydeco (ivacaftor) a cystic fibrosis
transmembrane conductance regulator
(CFTR) potentiator beneficial in children
2-5 yo
• Discontinue in patient with ALT or AST
levels ≥ 5xULN. Consider risk benefit
after resolution of transaminase
elevations
1/21/2016 medicalpress.com
Drug Approval
• FDA approves Zepatier (elbasvir and
grazoprevir) with or without ribavirin
for treatment of chronic hepatitic C
genotypes 1 and 4 infections in adult
patients
• Another treatment option that doesn’t
require use of interferon
1/28/2016 fda.gov
Speedy FDA Review
• Hepatitis C combo
sofosbuvir/velpatasvir was granted
speedy review
• It is beneficial in Hepatitis C
genotypes 1,2,4,5 and 6
• Efficacy of 99-100% has been
demonstrated with this combination
1/5/2016 fiercepharma.com, NEJM 2015; 373:2599-2607
New Formulation
• FDA approves Dexilant SoluTab
(dexlansoprazole) delayed release
orally disintegrating tablets (ODT)
• Indicated for treatment of GERD and
maintenance of healed erosive
esophagitis and relief of heartburn in
adults ≥ 18 yo
1/29/2016 www.formkit.com
Drug Approval
• FDA approves Adzenys XR-ODT
(amphetamine) for treatment of ADHD
in patients ≥ 6yo
• This oral disintegrating tablet is dosed
once daily, available in 6 dosage
strengths, equivalent to the Adderall
XR dosage strengths
1/27/2016 reuters.com
Patent Expirations
• Crestor (rosuvastatin) patent expected
to expire in July 2016
01/18/2016 forbes.com